NCX 899 is part of NicOx' proprietary nitric oxide-donating technology that may have the potential to improve blood pressure lowering activity of antihypertensive agents. In the preclinical study,
The FDA said they reviewed 103 psychiatric reports including suicidal behaviour from August 2005 to July 2006. Three deaths were recorded in the reports. Most of the events
Symbicort is a newly approved, twice-daily, inhaled combination therapy containing budesonide, a corticosteroid, and formoterol, a rapid and long-acting beta2-agonist. Symbicort is for asthma patients not adequately controlled
GlaxoSmithKline brought a patent lawsuit against Spectrum in 2005 alleging that the Imitrex patent has been infringed. Spectrum received approval from the FDA for the generic version of
The build up of plaque in the arteries is called atherosclerosis. The study is the largest and longest study to examine the effects of Actos, also known as
Roche has requested the approval of Tarceva as a treatment for patients who have not responded or are not able to tolerate the chemotherapy Docetaxel. Andrew Dillon, National
Diabetic retinopathy (DR) occurs when diabetes damages the small blood vessels in the retina, a part of the eye that is needed for vision. This damage can lead
According to the two companies, the eye products currently have a combined US market size of approximately $170 million. Under the terms of the agreement, FDC will fund
Under the merger agreement, Solexa's stockholders will receive shares of Illumina common stock valued at $14 per Solexa share. In addition, Illumina has entered into a definitive securities
Galvus is one of a new class of diabetes drugs known as DPP-4 inhibitors. Another DPP-4 inhibitor, Merck's Januvia, is ahead in development as it was approved last
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.